Insights into the classification of myasthenia gravis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Akaishi, Tetsuya ^a   Yamaguchi, Takuhiro ^a   Suzuki, Yasushi ^b   Nagane, Yuriko ^c   Suzuki, Shigeaki ^d   Murai, Hiroyuki ^e   Imai, Tomihiro ^f   Motomura, Masakatsu ^g   Fujihara, Kazuo ^a   Aoki, Masashi ^a   Utsugisawa, Kimiaki ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SENDAI CITY MEDICAL CENTER   (Japan)

^c Department of Neurology   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f SAPPORO MEDICAL UNIVERSITY   (Japan)

^g NAGASAKI INSTITUTE OF APPLIED SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; CLUSTER ANALYSIS; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NORMAL DISTRIBUTION; ONSET AGE; THYMOMA; THYMUS HYPERPLASIA; COMPLICATION; IMMUNOLOGY; PATHOLOGY; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AGE OF ONSET; AGED; CLUSTER ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYASTHENIA GRAVIS; THYMOMA; THYMUS NEOPLASMS; YOUNG ADULT;

EID: 84906991505     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106757     Document Type: Article

References (9)

1. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475-490.
2. Suzuki S, Utsugisawa K, Suzuki N (2013) Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 84: 989-994.
3. Aarli JA (1999) Late-onset myasthenia gravis, a changing scene. Arch Neurol 56: 25-27.
4. Murai H, Masuda M, Utsugisawa K, Nagane Y, Suzuki S, et al. (2014) Clinical features and treatment status of adult myasthenia gravis in Japan. Clin Exp Neuroimmunol 5: 84-91.
5. Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, et al. (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12: 875-884.
6. Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Murai H, et al. (2014) Healthrelated quality of life and treatment targets in myasthenia gravis. Muscle Nerve: In press.
7. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, et al. (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16-23.
8. Olsen SF, Matuzzi M, Elliott P (1996) Cluster analysis and disease mapping-why, when, and how? A step by step guide. BMJ 313: 863-866.
9. Rousseeuw PJ (1987) Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 20: 53-65.